ReviewSaudi journal of anaesthesia
Oliceridine and its potential to revolutionize GI endoscopy sedation.
Review in Saudi journal of anaesthesia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Oliceridine versus Sufentanil for Postoperative Recovery and Opioid-Related Adverse Events in Patients Undergoing Thoracoscopic Lobectomy: A Randomized Double-Blind Controlled Trial.Drug design, development and therapy · 2026Trial
- Oliceridine for Analgesia in Elderly Patients Undergoing Kyphoplasty: From a Clinical Trial.Pain research & management · 2026Trial
- The EDDrug design, development and therapy · 2026Trial
- Trial
- Safety and Efficacy of Oliceridine Combined with Propofol for Painless Gastroscopy: A Single-Center, Randomized, Parallel Controlled Clinical Trial.Drug design, development and therapy · 2026Trial
- Effective Dose of Oliceridine Fumarate Co-Administered with Remimazolam in Suppressing Gastroscope Insertion Responses for Adults.Drug design, development and therapy · 2025Trial
- Remimazolam-etomidate versus remimazolam-propofol for gastrointestinal endoscopy: A randomized controlled trial.PloS one · 2025Trial
- A Comparative Evaluation of the Safety and Efficacy of Oliceridine and Sufentanil in Gastrointestinal Endoscopy: A Single-Center, Randomized Controlled Trial.Drug design, development and therapy · 2025Trial
- Article
- Opioid analgesics for sedation-based gastrointestinal endoscopy.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Overview and Prospects of the Clinical Application of Oliceridine.Drug design, development and therapy · 2025Review
- Remimazolam for sedation in gastrointestinal endoscopy: A comprehensive review.World journal of gastrointestinal endoscopy · 2024Review
- Advances in Analgosedation and Periprocedural Care for Gastrointestinal Endoscopy.Life (Basel, Switzerland) · 2023Review
- Developments in procedural sedation for adults.BJA education · 2022Review
- A comprehensive review of remimazolam for sedation.Health psychology research · 2021Review
- Oliceridine- Opioid of the 21Saudi journal of anaesthesiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Providing sedation to patients undergoing gastrointestinal (GI) endoscopy is a controversial and emotive issue. The mainstay of sedation is propofol, whose administration is within the sole jurisdiction of anesthesia providers, at least in the USA. Attempts have been made to seize the authority by the GI community. One of the first attempts was the use of the prodrug of propofol -fospropofol. However, as the drug has a similar adverse effect profile as propofol in terms of respiratory depression, the FDA did not approve its use by providers other than those trained in airway management. Sedasys
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.